Drugs / EGFRt/BCMA-41BBz CAR T cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03070327 | Feb 2017 → Feb 2027 expected | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGFRt/BCMA-41BBz CAR T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03070327 ↗ |
| Modality | Cell therapy | “B-cell maturation antigen targeting CAR T cells for multiple myeloma (NCT03070327; n = 6)” PMID 32780846 ↗ Aug 2020 |